Dual anti-platelet therapy in secondary stroke prevention

By: Springer Healthcare IME
Listen for free

  • Summary

  • Professor Marc Fisher and Springer Healthcare IME invite you to listen to these three podcast discussions with experts in this therapy area. The podcasts focus on the clinical implications of recently published results from clinical trials involving the use of dual-anti-platelet therapy for secondary stroke prevention.
    Springer Healthcare. Part of the Springer Nature Group.
    Show More Show Less
Biological Sciences Hygiene & Healthy Living Physical Illness & Disease
Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • Discussion of the CHANCE and PRINCE clinical trials (with Marc Fisher and Liping Liu)

    Discussion of the CHANCE and PRINCE clinical trials (with Marc Fisher and Liping Liu)
    Mar 2 2021

    Professors Marc Fisher and Liping Liu discuss the CHANCE and PRINCE clinical trials focusing on their backgrounds and key results, and commenting on their clinical implications.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
    Show More Show Less
    18 mins
  • Discussion on the POINT trial (with Marc Fisher and Greg Albers)

    Discussion on the POINT trial (with Marc Fisher and Greg Albers)
    Mar 2 2021

    Professor Marc Fisher and Dr Greg Albers discuss the POINT trial, also commenting on when to consider ticagrelor versus clopidogrel.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
    Show More Show Less
    18 mins
  • Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)

    Discussion on the THALES trial and the clinical implications of the CHANCE 2 trial (with Marc Fisher and Clay Johnston)
    Mar 2 2021

    Professor Marc Fisher and Dr Clay Johnston discuss the THALES trial, explaining its rationale, key results and subgroup analyses, and also comment on the potential clinical implications of CHANCE 2.

    This programme is made possible thanks to an independent educational grant from AstraZeneca.

    Find more information at https://ime.springerhealthcare.com/programs/emerging-dual-anti-platelet-therapy-strategies-for-neurologists-in-secondary-stroke-prevention/
    Show More Show Less
    22 mins

What listeners say about Dual anti-platelet therapy in secondary stroke prevention

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available